New Retina Radio AAO Late-Breakers: PULSAR at 96 Weeks and Home OCT in Wet AMD

They’re here: the 96-week data on aflibercept 8 mg (Eylea, Regeneron) in wet AMD. Jean-François Korobelnik, MD, PhD stops by to review the 96-week data from PULSAR. How closely did the 96-week results match those at 48 weeks? And how many patients could be extended to 16-, 20-, or even 24-week intervals? Also, W. Lloyd Clark, MD, joins the show to discuss home-based OCT-guided management of wet AMD. How does home OCT fit into a patient’s life—and how might it shape the future of care? Listen here to find out. This Editorially independent content is supported with advertising.

Editorially Independent content supported by Genentech.

Other Podcast Episodes

11.13.25

AAO '25: GLP-1s and AMD, and Parity in Retina Care

Aleksandra Rachitskaya, MD; and Julia Haller, MD

Editorially independent content, supported by Genentech.

11.10.25

Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE

Rahul Khurana, MD; and Arshad Khanani, MD, MA

Editorially independent content, supported by Genentech.

11.06.25

AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt Disease

Peter Kaiser, MD; and Michel Michaelides, MD

Editorially independent content, supported by Genentech.

10.23.25

Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDR

Allen Ho, MD; and Charles Wykoff, MD, PhD

Editorially independent content, supported by Genentech.

09.04.25

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

David Lally, MD; and Ehsan Rahimy, MD

Editorially independent content, supported by Genentech

08.21.25

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders

John Kitchens, MD; Krishna Mukkamala, MD

Editorially independent content, supported by Genentech

06.12.25

Duke AVS Clips: PVR, DR, Imaging, and MTM

Jason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed

Editorially independent content

06.09.25

Duke AVS Clips: Pediatrics, Anesthesia Trends, and AI

Lejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD

Editorially independent content

06.05.25

Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDs

Avni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD

Editorially independent content

05.29.25

ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

Marion Munk, MD, PhD; and Diana Do, MD

Editorially independent content, supported by Genentech

05.22.25

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

Editorially independent content, supported by Genentech

12.05.24

AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer's

Adrienne Scott, MD; and Dilraj Grewal, MD

Editorially independent content supported by Genentech.

11.14.24

AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA

Durga S. Borkar, MD, MMCi; and Alex Melamud, MD

Editorially independent content supported by Genentech.

11.07.24

AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD

Jeremiah Brown, MD, MS; and Eric Schneider, MD

Editorially independent content supported by Genentech.

10.31.24

AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining Reimbursement

Rahul Khurana, MD; and Paul Hahn, MD, PhD

Editorially independent content supported by Genentech.

10.09.24

Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR

Ted Leng, MD; and Michael Klufas, MD

Editorially Independent content supported by Apellis.

09.05.24

ASRS ’24: C1q Inhibition and Metformin for AMD

Joel Pearlman, MD, PhD; and Dimitra Skondra, MD

Editorially Independent content supported by Genentech.

08.22.24

ASRS ’24: PAVILION at 100 Weeks

Margaret Chang, MD

Editorially Independent content supported by Genentech.

08.08.24

ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings

Katherine Talcott, MD; and Sunir Garg, MD

Editorially Independent content supported by Genentech.

06.05.24

ARVO 2024 Coverage: UWF Leakage in Protocol AA, Machine Learning, and GA's Link to Anxiety/Depression

Justis Ehlers, MD; and Lisa Faia, MD

Editorially Independent content supported by Genentech.

05.17.24

ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE

Philip Storey, MD; and Prof. Sobha Sivaprasad

Editorially Independent content supported by Genentech.

12.14.23

AAO ’23: Downward Trends in Reimbursement and ChatGPT in the Retina Clinic

John Thompson, MD and Raymond Iezzi, MD

Editorially Independent content supported by Genentech.

11.30.23

AAO ’23: Real-World Faricimab Patterns and Improving GA Assessments

Sophie Bakri, MD; and Karl Csaky, MD, PhD

Editorially Independent content supported by Genentech.

11.22.23

New Retina Radio AAO Late-Breakers: PULSAR at 96 Weeks and Home OCT in Wet AMD

Jean-François Korobelnik, MD, PhD; and W. Lloyd Clark, MD

Editorially Independent content supported by Genentech.

11.13.23

New Retina Radio AAO Late-Breakers: ALTITUDE and DIAMOND

Mark Barakat, MD; and And Hani Salehi-Had, MD

Editorially Independent content supported by Genentech.

09.01.23

ASRS ’23: Pegcetacoplan Extension Study, and Comparison of Pegcetacoplan and Avacincaptad Pegol

Nathan C. Steinle, MD; and Paul Hahn, MD, PhD

Editorially Independent content supported by Genentech.

08.11.23

ASRS ’23: Missed Injections for AMD/DME/RVO and Anatomic Response to Vabysmo in Wet AMD

Christina Y. Weng, MD, MBA; and Nikolas JS London, MD

Editorially Independent content supported by Genentech.

05.18.23

New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3

Diana Do, MD; and Jennifer Lim, MD

Editorially Independent content supported by Genentech.

05.11.23

New Retina Radio ARVO Coverage: Faricimab in Wet AMD: Real-world and Phase 3 Data

Durga Borkar, MD, MMCi and Varun Chaudhary, MD

Editorially Independent content supported by Genentech.

12.09.22

AAO '22: Biosimilars’ Practice Implications and Year 2 of YOSEMITE/RHINE

George Williams, MD, and Caroline Baumal, MD

Editorially Independent content supported by Genentech.

12.01.22

AAO '22 Late-Breaking Talks: Gene Therapies for GA and XLRP

Michel Michaelides, BSc, MB, BS MD(Res), FRCOphth; and Jeffrey Heier, MD

Editorially Independent content supported by Genentech.

11.10.22

AAO '22: Biomarkers and AI in the OR

Joan Miller, MD; and Yannek Leiderman, MD, PhD

Editorially Independent content supported by Genentech.

11.03.22

AAO '22 Late-Breaking Talks: Biosimilar Phase 3 Data and TRUCKEE Update

Anat Loewenstein, MD; and Ramanath Bhandari, MD

Editorially Independent content supported by Genentech.

10.25.22

AAO '22: GATHER2 Study Results

Arshad Khanani, MD, MS

Editorially Independent content supported by Genentech.

09.15.22

ASRS Meeting Coverage Day 3: DR Biomarkers and Gene Tx for Achromatopsia

Jennifer Lim, MD; and Lejla Vajzovic, MD

Editorially Independent content supported by Genentech.

08.04.22

ASRS Meeting Coverage Day 2: Diabetic Eye Disease Updates

John Kitchens, MD; and Michael Allingham, MD, PhD

Editorially Independent content supported by Genentech.

07.28.22

ASRS Meeting Coverage Day 1: TALON and TRUCKEE in Wet AMD

Carl Regillo, MD; and Carl Danzig, MD

Editorially Independent content supported by Genentech.

06.09.22

ARVO Meeting Coverage Day 3: CANDELA and ARCHWAY Data

David Brown, MD and Robert Mittra, MD

Editorially Independent content supported by Genentech.

06.02.22

ARVO Meeting Coverage Day 2: Pipeline Therapies in GA

Allen C. Ho, MD and Jared Nielsen, MD, MBA

Editorially Independent content supported by Genentech.

05.26.22

ARVO Meeting Coverage Day 1: LIGHTSITE III and DERBY/OAKS at 18 Months

Editorially Independent content supported by Genentech.

12.17.21

AAO 2021: Updates in Uveitis and Trauma

Glenn Jaffe, MD; and Nicole Koulisis, MD

12.03.21

PALADIN for DME and ROP Updates From the ICROP

Michael Singer, MD; and R.V. Paul Chan, MD, MSc, MBA

11.30.21

AAO 2021 Late Breakers: DAVIO and NORSE-2

David Boyer, MD; and Firas Rahhal, MD

11.23.21

AAO 2021: Protocol W and Monitoring for Wet AMD

Raj Maturi, MD; and Usha Chakravarthy, MD

11.19.21

AAO 2021 Late Breakers: GATHER1 and ALTISSIMO

David Lally, MD; and Veeral Sheth, MD

11.05.21

ASRS 2021 Coverage: The Pipeline for Wet AMD and GA

Mark Barakat, MD; and Nancy Holekamp, MD

10.29.21

ASRS 2021 Coverage: Losing GA Patients to Follow-up and DME Meta-analysis

Durga Borkar, MD; and M. Ali Khan, MD

10.22.21

ASRS 2021 Coverage: ARCHWAY and TENAYA/LUCERNE

Chirag Jhaveri, MD; and Karl Csaky, MD

06.04.21

ARVO 2021 Coverage: NGM621 and COOG2

David Eichenbaum, MD; and Amy Schefler, MD

05.28.21

ARVO 2021: GATHER1 Study and CME After RRD Surgery

Veeral Sheth, MD; and Matthew Starr, MD

05.21.21

ARVO 2021 Coverage: TENAYA/LUCERNE Results—and Is Fluid OK in Wet AMD?

Arshad Khanani, MD, MA; and David Lally, MD

03.12.21

Angiogenesis 2021: Wet AMD

John Kitchens, MD; Diana Do, MD; and Carl Regillo, MD

03.04.21

Angiogenesis 2021: Geographic Atrophy

John Kitchens, MD; Pravin Dugel, MD, and SriniVas Sadda, MD

01.25.21

Clinical Impacts From AAO 2020: Drs. Singh, Ehlers, and Gillies

Rishi Singh, MD; Justis Ehlers, MD; and Mark Gillies, MD, PhD

12.17.20

Clinical Impacts From AAO 2020: Drs. Singh, Do, and Heier

Rishi Singh, MD; Diana Do, MD; and Jeffrey Heier, MD

12.07.20

DRCR Retina Network Protocol AB at AAO

Andrew Antoszyk, MD

12.02.20

AAO Late Breaker: IRIS Registry Data on GA

Ehsan Rahimy, MD

11.30.20

Coding Changes for 2021 at AAO

Joy Woodke

11.25.20

AAO Late Breaker: Ang-2 Mediation in DME Therapy

Karl Csaky, MD, PhD

11.23.20

Retinal Arteriolar Macroaneurysm and Anti-VEGF Therapy at AAO

J. Fernando Arevalo, MD, PhD

11.20.20

AAO Late Breaker: KSI-301 in DME Therapy

Arshad M. Khanani, MD, MA

11.18.20

ARCHWAY at AAO

Nancy Holekamp, MD

08.31.20

jCell Therapy for Retinitis Pigmentosa and Phase 2B Data

Anthony Joseph, MD

08.21.20

Treat-and-Extend in the Real World

Michael Singer, MD

08.12.20

Opioid Prescribing Patterns Among Retina Specialists

Yoshi Yonekawa, MD

08.04.20

Continuous Dosing in LADDER

Dilsher Dhoot, MD

06.30.20

Faricimab in Phase 2 and 3

Carl Danzig, MD

New Retina Radio:

New Retina Radio Meeting Coverage

New Retina Radio AAO Late-Breakers: PULSAR at 96 Weeks and Home OCT in Wet AMD

Other Podcast Episodes